# A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

> **NCT05851443** · PHASE2 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 240 (estimated)

## Conditions studied

- Moderate to Severe Asthma

## Interventions

- **DRUG:** povorcitinib
- **OTHER:** placebo
- **DRUG:** ICS-LABA

## Key facts

- **NCT ID:** NCT05851443
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-11
- **Primary completion:** 2026-06-15
- **Final completion:** 2027-01-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05851443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05851443, "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05851443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*